Literature DB >> 9046038

Immunohistochemical expression of Bcl-2 oncoprotein in EBV-associated nasopharyngeal carcinoma correlated to histological type and survival.

F J Vera-Sempere1, J S Burgos, M S Botella, C Morera.   

Abstract

Expression of Bcl-2 is associated with inhibition of apoptosis and extension of cell survival. In vitro Bcl-2 protein expression is up-regulated by the EBV-latency associated antigen latent membrane protein (LMP-1). We have investigated the relationship between the presence of EBV-DNA screened by means of sensitive nested-PCR, nasopharyngeal carcinoma (NPC) histological types according to two different schemata (WHO and Micheau classifications) and Bcl-2-124 immunohistochemical expression in 55 biopsy samples of NPC. EBV genome was detected in 100% of samples with sufficient DNA quality to support the previous view that all types of NPC are variants of EBV-infected neoplasia. Bcl-2 was observed in the basal layer of normal nasopharyngeal mucosa and also at cytoplasmic level in 42 of 55 (76.4%) NPC cases. Mitotic neoplastic cells usually showed strong cytoplasmic and chromosomal staining, a finding not well referred to previously. Bcl-2 expression was significantly associated (p<0.05) to undifferentiated NPC (UNPC) when a histological classification with only two major microscopical types was applied. No close correlations were found between the presence of EBV-DNA, NPC location, clinical stage and age or sex of the patients in relation to Bcl-2 positive expression. However, when comparing Bcl-2 expression and known survival mean of the patients, significant differences were observed (p<0.001) so that mean survivals were 31.1, 24.4, 52.2 and 54.1 months respectively for NPC patients with -, +, ++ and Bcl-2 immunoreactivity. Nevertheless this better clinical outcome in Bcl-2 NPC positive cases may depend on the histological type due to close relationship with UNPC. Only studies of larger series with long-term follow-up and multivariate analyses may document whether Bcl-2 expression is an independent prognostic marker in the evolution of NPC patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9046038

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  6 in total

Review 1.  Involvement of the Epstein-Barr virus in the nasopharyngeal carcinoma pathogenesis.

Authors:  Javier S Burgos
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

2.  BCL2L12 is a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma.

Authors:  Ali Fendri; Christos K Kontos; Abdelmajid Khabir; Raja Mokdad-Gargouri; Andreas Scorilas
Journal:  Mol Med       Date:  2010-12-08       Impact factor: 6.354

3.  Quantitative analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor.

Authors:  Ali Fendri; Christos K Kontos; Abdelmajid Khabir; Raja Mokdad-Gargouri; Alexandros Ardavanis; Andreas Scorilas
Journal:  Tumour Biol       Date:  2010-06-01

Review 4.  Locally advanced nasopharyngeal cancer.

Authors:  J F Ensley; E Youssef; H Kim; G Yoo
Journal:  Curr Treat Options Oncol       Date:  2001-02

5.  Absence of p53 alterations in nasopharyngeal carcinoma Spanish patients with Epstein-Barr virus infection.

Authors:  Javier S Burgos
Journal:  Virus Genes       Date:  2003-12       Impact factor: 2.332

6.  Quantitative expression analysis and prognostic significance of the BCL2-associated X gene in nasopharyngeal carcinoma: a retrospective cohort study.

Authors:  Christos K Kontos; Ali Fendri; Abdelmajid Khabir; Raja Mokdad-Gargouri; Andreas Scorilas
Journal:  BMC Cancer       Date:  2013-06-18       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.